Shares of Corcept Therapeutics Inc. (CORT) are up over 85% at $101.48 today, following encouraging data from its phase III trial of Relacorilant in patients with platinum-resistant ovarian cancer, dubbed ROSELLA.
In the ROSELLA trial, the enrolled 381 patients with platinum-resistant ovarian cancer, were randomized 1:1 to receive either Relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com